United States Biotechnology & Medical Research

Summit Therapeutics PLC (SUMM)

Track

Track

Summit Therapeutics PLC has recorded no insider trading activity within the last three months. The most recent transaction occurred on January 14, 2020, when a non-executive director executed a significant sale of shares. Historical records indicate various buying and selling patterns by company leadership spanning several years prior to this final reported event.
Ticker: SUMM Exchange: LSE
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Summit Therapeutics PLC. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Robert W. Duggan Non-Executive Director Executive Director
Transaction date
Sale
Price
191.93
Quantity 11,826
Value £844,420
Leopoldo Zambeletti Non-Executive Director Executive Director
Transaction date
Sale
Price
340.08
Quantity 15,112
Value £1,185,338
Leopoldo Zambeletti Non-Executive Director Executive Director
Transaction date
Sale
Price
481.34
Quantity 70,515
Value £4,640,334
Barry Price Non-Executive Director Executive Director
Transaction date
Sale
Price
0.37
Quantity 21,137
Value £7,715
Frank Armstrong Non-Executive Chairman Director
Transaction date
Purchase
Price
0.40
Quantity 25,000
Value £9,875
Glyn Owain Edwards Chief Executive Officer Officer
Transaction date
Purchase
Price
0.38
Quantity 150,000
Value £57,000
BLOCK IVAN E Non-Executive Director
Transaction date
Sale
Price
18.26
Quantity 772 -0.5%
Value US$14,097
BETTENDORF BLAISE B SVP/Chief Financial Officer Officer
Transaction date
Sale
Price
19.00
Quantity 3,000 -3.8%
Value US$57,000
BETTENDORF BLAISE B SVP/Chief Financial Officer Officer
Transaction date
Sale
Price
18.55
Quantity 2,500 -3.0%
Value US$46,375
BETTENDORF BLAISE B SVP/Chief Financial Officer Officer
Transaction date
Sale
Price
18.95
Quantity 1,000 -1.5%
Value US$18,950
FURMAN J EARLE JR Non-Executive Director
Transaction date
Sale
Price
19.00
Quantity 430 -0.6%
Value US$8,170
FURMAN J EARLE JR Non-Executive Director
Transaction date
Sale
Price
19.00
Quantity 90 -0.1%
Value US$1,710
BLOCK IVAN E Non-Executive Director
Transaction date
Purchase
Price
18.90
Quantity 1,180 +0.7%
Value US$22,302
FURMAN J EARLE JR Non-Executive Director
Transaction date
Sale
Price
18.81
Quantity 1,000 -1.4%
Value US$18,810
FURMAN J EARLE JR Non-Executive Director
Transaction date
Sale
Price
18.32
Quantity 1,000 -1.4%
Value US$18,320
BETTENDORF BLAISE B SVP/Chief Financial Officer Officer
Transaction date
Sale
Price
18.00
Quantity 2,500 -3.7%
Value US$45,000
BETTENDORF BLAISE B SVP/Chief Financial Officer Officer
Transaction date
Sale
Price
18.60
Quantity 500 -0.9%
Value US$9,300
FURMAN J EARLE JR
Transaction date
Sale
Price
18.00
Quantity 5,000 -6.6%
Value US$90,000
FURMAN J EARLE JR
Transaction date
Sale
Price
19.00
Quantity 738 -1.0%
Value US$14,022
HOUSER JOHN W Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 365 +0.4%
Value US$6,570
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2020-01-15 2020-01-14 S Sale Robert W. Duggan

Non-Executive Director

Executive Director
11,826
191.93
£844,420 		11,826 191.93 £844,420
2018-10-24 2018-10-24 S Sale Leopoldo Zambeletti

Non-Executive Director

Executive Director
15,112
340.08
£1,185,338 		15,112 340.08 £1,185,338
2018-07-19 2018-07-18 S Sale Leopoldo Zambeletti

Non-Executive Director

Executive Director
70,515
481.34
£4,640,334 		70,515 481.34 £4,640,334
2018-07-19 2018-07-18 S Sale Barry Price

Non-Executive Director

Executive Director
21,137
0.37
£7,715 		21,137 0.37 £7,715
2018-07-17 2018-07-16 B Purchase Frank Armstrong

Non-Executive Chairman

Director
25,000
0.40
£9,875 		25,000 0.40 £9,875
2018-07-16 2018-07-13 B Purchase Glyn Owain Edwards

Chief Executive Officer

Officer
150,000
0.38
£57,000 		150,000 0.38 £57,000
2004-08-30 2004-08-25 S Sale BLOCK IVAN E Non-Executive Director
772 -0.5%
18.26
US$14,097 		772 -0.5% 18.26 US$14,097
2004-08-18 2004-08-18 S Sale BETTENDORF BLAISE B

SVP/Chief Financial Officer

Officer
3,000 -3.8%
19.00
US$57,000 		3,000 -3.8% 19.00 US$57,000
2004-08-17 2004-08-16 S Sale BETTENDORF BLAISE B

SVP/Chief Financial Officer

Officer
2,500 -3.0%
18.55
US$46,375 		2,500 -3.0% 18.55 US$46,375
2004-08-03 2004-08-03 S Sale BETTENDORF BLAISE B

SVP/Chief Financial Officer

Officer
1,000 -1.5%
18.95
US$18,950 		1,000 -1.5% 18.95 US$18,950
2004-06-15 2004-06-15 S Sale FURMAN J EARLE JR Non-Executive Director
430 -0.6%
19.00
US$8,170 		430 -0.6% 19.00 US$8,170
2004-06-15 2004-06-14 S Sale FURMAN J EARLE JR Non-Executive Director
90 -0.1%
19.00
US$1,710 		90 -0.1% 19.00 US$1,710
2004-06-08 2004-06-07 B Purchase BLOCK IVAN E Non-Executive Director
1,180 +0.7%
18.90
US$22,302 		1,180 +0.7% 18.90 US$22,302
2004-06-07 2004-06-07 S Sale FURMAN J EARLE JR Non-Executive Director
1,000 -1.4%
18.81
US$18,810 		1,000 -1.4% 18.81 US$18,810
2004-06-02 2004-06-02 S Sale FURMAN J EARLE JR Non-Executive Director
1,000 -1.4%
18.32
US$18,320 		1,000 -1.4% 18.32 US$18,320
2004-03-31 2004-03-30 S Sale BETTENDORF BLAISE B

SVP/Chief Financial Officer

Officer
2,500 -3.7%
18.00
US$45,000 		2,500 -3.7% 18.00 US$45,000
2004-03-03 2004-03-02 S Sale BETTENDORF BLAISE B

SVP/Chief Financial Officer

Officer
500 -0.9%
18.60
US$9,300 		500 -0.9% 18.60 US$9,300
2004-02-24 2004-02-24 S Sale FURMAN J EARLE JR
5,000 -6.6%
18.00
US$90,000 		5,000 -6.6% 18.00 US$90,000
2004-02-24 2004-02-23 S Sale FURMAN J EARLE JR
738 -1.0%
19.00
US$14,022 		738 -1.0% 19.00 US$14,022
2004-01-15 2004-01-06 B Purchase HOUSER JOHN W Non-Executive Director
365 +0.4%
18.00
US$6,570 		365 +0.4% 18.00 US$6,570
Explore more

More insider trading research around Summit Therapeutics PLC

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America